Advances in studies on the therapy with proteasome inhibitor Bortezomib

The ubiquitin-proteasome pathway is one of important pathways during protein selective degradation in organism which participates in many intracellular physiological and biochemical processes.Proteasome inhibitor can block the degradation of quantity of regulatory proteins and induce intracellular signal pathway disorder and over loading,which will result in cell growth inhibition as well as the delay and even stop of tumor invasion.As a proteasome inhibitor,Bortezomib can inhibit cell growth of multiple myeloma and inducc apoptosis of tumor cells.Further more,it has significant effect on other hematological malignancies,as well as other solid tumors.At the same time,Bortezomib can overcome drug resistance in chemotherapy.This article reviewed studies on therapy with proteasome inhibitor Bortezomib.